Contineum Therapeutics, Inc. Class A Share Price

Contineum Therapeutics, Inc. Class A Share Price

NASDAQ: CTNM | Micro Cap
$9.31
+$0.13 (1.36%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Contineum Therapeutics, Inc. Class A Stock Performance

Open
$9.33
Prev. Close
$9.19
Circuit Range
N/A
Day Range
$9.30 - $9.83
Year Range
$6.74 - $17.77
Volume
44,225
Average Traded
$9.43

Contineum Therapeutics, Inc. Class A Share Price Today

As of 30 October 2026, Contineum Therapeutics, Inc. Class A's share price is $9.31. The stock opened at $9.33, compared to its previous close of $9.19. During today's trading session, Contineum Therapeutics, Inc. Class A's share price traded between $9.30 and $9.83, with an average price of $9.57. Over the past 52 weeks, the stock has recorded a high of $17.77 and a low of $6.74. In terms of performance, Contineum Therapeutics, Inc. Class A's share price has declined by 27.23% over the last six months and is down 15.32% on a year-on-year basis.

Contineum Therapeutics, Inc. Class A Share Price Chart

Line chart of the Contineum Therapeutics, Inc. Class A price trend over the selected period. The price rose overall, ranging from 8.93 to 9.83, ending at 9.32.
$9.30$9.83
L
Show Current Price
H

Contineum Therapeutics, Inc. Class A Stock Fundamentals & Key Indicators

Market Cap
$258.03M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.53
Revenue (TTM)
$0.00
Return On Equity (TTM)
-24.02%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-18.45%

Contineum Therapeutics, Inc. Class A Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$12.79-$15.16-$14.46-$15.15
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-18.53%4.62%-4.77%

Contineum Therapeutics, Inc. Class A Annual Profit & Loss

All figures in USD

Particulars20242025
Revenue$0.00$0.00
Net Profit-$42.26-$59.98
Net Profit MarginN/AN/A
Income ChangeN/A-41.93%

About Contineum Therapeutics, Inc. Class A

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Contineum Therapeutics, Inc. Class A Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$13.28
$9.30
-31.06%
Sep 2026
$15.99
$13.49
-21.71%
Aug 2026
$15.45
$17.23
+11.16%
Jul 2026
$16.36
$15.50
-5.37%
Jun 2026
$13.22
$16.38
+21.51%
May 2026
$13.08
$13.48
+5.31%
Apr 2026
$13.21
$12.80
-1.92%
Mar 2026
$14.72
$13.05
-14.54%
Feb 2026
$14.94
$15.27
+7.84%
Jan 2026
$11.65
$14.16
+23.99%
Dec 2025
$10.56
$11.42
+3.40%
Nov 2025
$10.90
$11.04
+0.41%

CTNM Share Price FAQs